235 related articles for article (PubMed ID: 37133900)
1. Nanoparticle-Mediated CD47-SIRPα Blockade and Calreticulin Exposure for Improved Cancer Chemo-Immunotherapy.
Luo JQ; Liu R; Chen FM; Zhang JY; Zheng SJ; Shao D; Du JZ
ACS Nano; 2023 May; 17(10):8966-8979. PubMed ID: 37133900
[TBL] [Abstract][Full Text] [Related]
2. Nanoparticle-Enabled Dual Modulation of Phagocytic Signals to Improve Macrophage-Mediated Cancer Immunotherapy.
Zhang YR; Luo JQ; Zhang JY; Miao WM; Wu JS; Huang H; Tong QS; Shen S; Leong KW; Du JZ; Wang J
Small; 2020 Nov; 16(46):e2004240. PubMed ID: 33107142
[TBL] [Abstract][Full Text] [Related]
3. An "eat me" combinatory nano-formulation for systemic immunotherapy of solid tumors.
Abdel-Bar HM; Walters AA; Lim Y; Rouatbi N; Qin Y; Gheidari F; Han S; Osman R; Wang JT; Al-Jamal KT
Theranostics; 2021; 11(18):8738-8754. PubMed ID: 34522209
[No Abstract] [Full Text] [Related]
4. A siRNA-Assisted Assembly Strategy to Simultaneously Suppress "Self" and Upregulate "Eat-Me" Signals for Nanoenabled Chemo-Immunotherapy.
Zhang Y; Zhang Z; Li S; Zhao L; Li D; Cao Z; Xu X; Yang X
ACS Nano; 2021 Oct; 15(10):16030-16042. PubMed ID: 34544242
[TBL] [Abstract][Full Text] [Related]
5. Promising alternatives of CD47 monoclonal antibody: an injectable degradable hydrogel loaded with PQ912 for postoperative immunotherapy effectively blocks CD47-SIRPα signal.
Li C; Liu Y; Li D; Wang Q; Zhou S; Zhang H; Wang Y; He Z; Liu H; Sun J
Theranostics; 2022; 12(10):4581-4598. PubMed ID: 35832081
[No Abstract] [Full Text] [Related]
6. SIRPα-Fc fusion protein IMM01 exhibits dual anti-tumor activities by targeting CD47/SIRPα signal pathway via blocking the "don't eat me" signal and activating the "eat me" signal.
Yu J; Li S; Chen D; Liu D; Guo H; Yang C; Zhang W; Zhang L; Zhao G; Tu X; Peng L; Liu S; Bai X; Song Y; Jiang Z; Zhang R; Tian W
J Hematol Oncol; 2022 Nov; 15(1):167. PubMed ID: 36384978
[TBL] [Abstract][Full Text] [Related]
7. Bionic lipoprotein loaded with chloroquine-mediated blocking immune escape improves antitumor immunotherapy.
Dong Q; Han D; Li B; Yang Y; Ren L; Xiao T; Zhang J; Li Z; Yang H; Liu H
Int J Biol Macromol; 2023 Jun; 240():124342. PubMed ID: 37030459
[TBL] [Abstract][Full Text] [Related]
8. CD47/SIRPα blocking peptide identification and synergistic effect with irradiation for cancer immunotherapy.
Wang H; Sun Y; Zhou X; Chen C; Jiao L; Li W; Gou S; Li Y; Du J; Chen G; Zhai W; Wu Y; Qi Y; Gao Y
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33020240
[TBL] [Abstract][Full Text] [Related]
9. "Velcro" engineering of high affinity CD47 ectodomain as signal regulatory protein α (SIRPα) antagonists that enhance antibody-dependent cellular phagocytosis.
Ho CC; Guo N; Sockolosky JT; Ring AM; Weiskopf K; Özkan E; Mori Y; Weissman IL; Garcia KC
J Biol Chem; 2015 May; 290(20):12650-63. PubMed ID: 25837251
[TBL] [Abstract][Full Text] [Related]
10. Targeting HDAC6 improves anti-CD47 immunotherapy.
Gracia-Hernandez M; Yende AS; Gajendran N; Alahmadi Z; Li X; Munoz Z; Tan K; Noonepalle S; Shibata M; Villagra A
J Exp Clin Cancer Res; 2024 Feb; 43(1):60. PubMed ID: 38414061
[TBL] [Abstract][Full Text] [Related]
11. Discovery of a novel small molecule as CD47/SIRPα and PD-1/PD-L1 dual inhibitor for cancer immunotherapy.
Jin S; Wang H; Li Y; Yang J; Li B; Shi P; Zhang X; Zhou X; Zhou X; Niu X; Wu M; Wu Y; Zhai W; Qi Y; Gao Y; Zhao W
Cell Commun Signal; 2024 Mar; 22(1):173. PubMed ID: 38462636
[TBL] [Abstract][Full Text] [Related]
12. The CD47-SIRPα axis is a promising target for cancer immunotherapies.
Hao Y; Zhou X; Li Y; Li B; Cheng L
Int Immunopharmacol; 2023 Jul; 120():110255. PubMed ID: 37187126
[TBL] [Abstract][Full Text] [Related]
13. Extracellular Vesicles-Derived Hybrid Nanoplatforms for Amplified CD47 Blockade-Based Cancer Immunotherapy.
Tang L; Yin Y; Cao Y; Fu C; Liu H; Feng J; Wang W; Liang XJ
Adv Mater; 2023 Sep; 35(35):e2303835. PubMed ID: 37384818
[TBL] [Abstract][Full Text] [Related]
14. Targeting CD47 in Anaplastic Thyroid Carcinoma Enhances Tumor Phagocytosis by Macrophages and Is a Promising Therapeutic Strategy.
Schürch CM; Roelli MA; Forster S; Wasmer MH; Brühl F; Maire RS; Di Pancrazio S; Ruepp MD; Giger R; Perren A; Schmitt AM; Krebs P; Charles RP; Dettmer MS
Thyroid; 2019 Jul; 29(7):979-992. PubMed ID: 30938231
[No Abstract] [Full Text] [Related]
15. Improving nanochemoimmunotherapy efficacy by boosting "eat-me" signaling and downregulating "don't-eat-me" signaling with
Pang G; Wei S; Zhao J; Wang FJ
J Mater Chem B; 2023 Dec; 11(48):11562-11577. PubMed ID: 37982298
[TBL] [Abstract][Full Text] [Related]
16. Codelivery of anti-CD47 antibody and chlorin e6 using a dual pH-sensitive nanodrug for photodynamic immunotherapy of osteosarcoma.
Xiao J; Xiao H; Cai Y; Liao J; Liu J; Yao L; Li S
Oncol Res; 2024; 32(4):691-702. PubMed ID: 38560565
[TBL] [Abstract][Full Text] [Related]
17. Immunostimulant Hydrogel-Guided Tumor Microenvironment Reprogramming to Efficiently Potentiate Macrophage-Mediated Cellular Phagocytosis for Systemic Cancer Immunotherapy.
Liang JL; Jin XK; Luo GF; Zhang SM; Huang QX; Lin YT; Deng XC; Wang JW; Chen WH; Zhang XZ
ACS Nano; 2023 Sep; 17(17):17217-17232. PubMed ID: 37584451
[TBL] [Abstract][Full Text] [Related]
18. Design of Light-Activated Nanoplatform through Boosting "Eat Me" Signals for Improved CD47-Blocking Immunotherapy.
Lu Y; Gong Y; Zhu X; Dong X; Zhu D; Ma G
Adv Healthc Mater; 2022 May; 11(10):e2102712. PubMed ID: 34981660
[TBL] [Abstract][Full Text] [Related]
19. Exosome-SIRPα, a CD47 blockade increases cancer cell phagocytosis.
Koh E; Lee EJ; Nam GH; Hong Y; Cho E; Yang Y; Kim IS
Biomaterials; 2017 Mar; 121():121-129. PubMed ID: 28086180
[TBL] [Abstract][Full Text] [Related]
20. CD47/SIRPα axis: bridging innate and adaptive immunity.
van Duijn A; Van der Burg SH; Scheeren FA
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35831032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
